The clean interim review without sample size change or safety issues is a positive signal for rademikibart's development. Traders should monitor mid-2026 topline data as the next major catalyst, which could drive valuation if results support advancement to Phase 3.
Price Chart
Executive Summary
Connect Biopharma announced that the independent Data Monitoring Committee (DMC) completed its interim analysis of efficacy for the Phase 2 Seabreeze STAT trials of rademikibart in asthma and COPD, with no recommendation to change sample size, allowing enrollment to continue as planned. Topline data are expected mid-2026.
Key Facts
- Independent Data Monitoring Committee (DMC) completed pre-specified interim analysis of efficacy for Phase 2 Seabreeze STAT trials in asthma and COPD
- No recommendation to change sample size, so enrollment continues as planned
- No safety concerns reported; no treatment-related serious adverse events or discontinuations
- Topline data from both studies expected mid-2026
- Company plans to meet with FDA to discuss Phase 3 program following data readout
Financial Impact
No immediate financial impact, but progression of Phase 2 trials de-risks development and supports future funding or partnership potential. Milestone eligibility of up to $110M from Simcere remains intact.
Risk Factors
- Topline data in mid-2026 may not meet efficacy expectations despite positive interim review
- As a clinical-stage biotech, Connect Biopharma remains dependent on trial outcomes and future funding rounds
- No guarantee that Phase 3 discussions with FDA will result in an agreed path forward
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001835268-26-000016 |
| Exhibit: exhibit991-seabreezeinteri.htm | 0001835268-26-000016 |
| Document: 0001835268-26-000016-index-headers.html | 0001835268-26-000016 |
| Document: 0001835268-26-000016-index.html | 0001835268-26-000016 |
| Document: 0001835268-26-000016.txt | 0001835268-26-000016 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 6, 2026 21d ago | SC 13G | $0.9450 $0.9090 | ▼ −3.81% | ▼ −2.83% | $0.8430 (−10.79%) |
Sep 30, 2026 27d ago | 8-K | $1.10 $0.9450 | ▼ −14.09% | ▼ −16.00% | $0.8430 (−23.36%) |
Sep 30, 2026 27d ago | Press Release | $1.10 $0.9447 | ▼ −14.12% | ▼ −16.03% | $0.8430 (−23.36%) |
Sep 15, 2026 6w ago | 8-K | $1.17 $1.28 | ▲ +9.40% | ▲ +8.58% | $0.8430 (−27.95%) |
May 12, 2026 24w ago | 8-K | $2.68 $2.38 | ▼ −11.19% | ▼ −11.27% | $0.8430 (−68.54%) |
May 12, 2026 24w ago | Press Release | $2.68 $2.38 | ▲ +11.19% | ▲ +11.27% | $0.8430 (+68.54%) |
Apr 23, 2026 26w ago | 8-K | $2.52 $2.53 | ▲ +0.40% | ▼ −1.08% | $0.8430 (−66.55%) |
Mar 31, 2026 30w ago | 8-K | $2.72 $2.78 | ▲ +2.21% | ▼ −1.56% | $0.8430 (−69.01%) |
Mar 30, 2026 30w ago | Press Release | $2.90 $2.82 | ▼ −2.76% | ▼ −7.06% | $0.8430 (−70.93%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers